Dena A. Jerjees
Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer
Jerjees, Dena A.; Alabdullah, M.; Green, Andrew R.; Alshareeda, Alaa; Macmillan, R. D.; Ellis, Ian O.; Rakha, Emad A.
Authors
M. Alabdullah
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Alaa Alshareeda
R. D. Macmillan
Ian O. Ellis
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Abstract
The definition of Luminal-B subclass of breast cancer (BC) varies in literature. In this study, we have compared the proliferation status; assessed using KI67 labeling index (KI67-LI), and HER2-expression in estrogen receptor positive (ER+) BC to assess their impact on the biological and clinical characteristics of luminal-BC. 1547 (73.8 %) well-characterized clinically annotated stage I–III ER + BC were assessed for expression of KI67, HER2 (ASCO guidelines), and a large panel of relevant biomarkers (no = 37). 46.3 % of the cases show high KI67-LI (>13 %) and 8.4 % show HER2+ and both markers are positively associated with younger age, higher tumor grade and poorer outcome. High KI67-LI and HER2+ are associated with upregulation of ER-coactivators and proliferation-related markers and with downregulation of good prognostic markers. High KI67-LI is associated with larger size, advanced stage, and lymphovascular invasion (LVI) and with downregulation of luminal-enriched and DNA-damage repair markers. In contrast, HER2+ is associated with upregulation of ER-regulated proteins and E-cadherin. When analysis is restricted to high KI67-LI subgroup, HER2+ shows an association with upregulation of differentiation-associated proteins and E-cadherin. Conversely, within HER2+ class, high KI67-LI maintains its association with downregulation of differentiation-associated/luminal-enriched proteins. Outcome analyses indicate that both markers are independently associated with shorter survival but HER2+ is associated with a worse outcome. Although both are associated with high proliferation and poor prognosis within ER + BC, HER2+ is less frequent than high KI67-LI. Unlike KI67, HER2 seems to independently drive the aggressive behavior of ER+ tumors without downregulation of luminal proteins.
Citation
Jerjees, D. A., Alabdullah, M., Green, A. R., Alshareeda, A., Macmillan, R. D., Ellis, I. O., & Rakha, E. A. (2014). Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast Cancer Research and Treatment, 145(2), 317-330. https://doi.org/10.1007/s10549-014-2941-7
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 26, 2014 |
Online Publication Date | Apr 18, 2014 |
Publication Date | 2014-06 |
Deposit Date | Oct 17, 2018 |
Journal | Breast Cancer Research and Treatment |
Print ISSN | 0167-6806 |
Electronic ISSN | 1573-7217 |
Publisher | Springer Verlag |
Peer Reviewed | Peer Reviewed |
Volume | 145 |
Issue | 2 |
Pages | 317-330 |
DOI | https://doi.org/10.1007/s10549-014-2941-7 |
Public URL | https://nottingham-repository.worktribe.com/output/1172407 |
Publisher URL | https://link.springer.com/article/10.1007%2Fs10549-014-2941-7 |
You might also like
Cell Division Cycle 6 (CDC6) is an Independent Prognostic Biomarker in Breast Cancer
(2024)
Journal Article
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search